Apnimed Announces Completion of Enrollment in Phase 3 LunAIRo Study of AD109, the Potential First Nighttime Oral Treatment for Obstructive Sleep Apnea Apnimed Completes Enrollment in Ph3 LunAIRo Study of AD109, Potential 1st Nighttime Oral Tx for Obstructive Sleep Apnea; Presents Study Design at ATS2024

Apnimed Named 2024 Best Places to Work Company by the Boston Business Journal Apnimed Named 2024 Best Places to Work Company by the Boston Business Journal

Apnimed Announces New Leadership Appointments as the Company Builds Its Commercial and Human Resource Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea Apnimed Announces New Leadership Appointments as It Builds Commercial & HR Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for OSA

Hexatronic stärker närvaron på den australiska marknaden genom förvärv av två ledande telekombolag Hexatronic Group AB (publ) 556168-6360 Pressmeddelande 2 augusti, 2021 Hexatronic stärker närvaron på den australiska marknaden genom förvärv av två ledande telekombolag Hexatronic Group AB (publ)...

Hexatronic strengthens Australian market presence through acquisition of two leading telecom businesses Hexatronic Group AB (publ) 556168-6360 Press Release August 2, 2021 Hexatronic strengthens Australian market presence through acquisition of two leading telecom businesses Hexatronic Group AB...